Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PRAX Praxis Precision Medicines Inc
- Stocks
- Healthcare
- NASDAQ: PRAX
Price (delayed)
$42.26
Market cap
$860.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$10.78
Enterprise value
$696.29M
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights
Highlights
PRAX's equity has soared by 91% YoY
The debt has dropped by 52% year-on-year and by 22% since the previous quarter
PRAX's EPS is up by 28% year-on-year but it is down by 6% since the previous quarter
The net income has plunged by 70% YoY and by 16% from the previous quarter
The quick ratio has declined by 25% year-on-year and by 21% since the previous quarter
Key stats
What are the main financial stats of PRAX
Market
Valuations
Earnings
Shares outstanding
20.37M
Market cap
$860.79M
Enterprise value
$696.29M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.94
Price to sales (P/S)
109.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
85.73
Revenue
$8.12M
Gross profit
$8.12M
Operating income
-$233.01M
Net income
-$212.56M
EBIT
-$212.56M
EBITDA
-$211.31M
Free cash flow
-$163.91M
Per share
Balance sheet
Liquidity
EPS
-$10.78
EPS diluted
-$10.78
Free cash flow per share
-$7.78
Book value per share
$21.78
Revenue per share
$0.39
TBVPS
$22.74
Total assets
$478.74M
Total liabilities
$39.52M
Debt
$1.07M
Equity
$439.21M
Working capital
$294.05M
Debt to equity
0
Current ratio
8.44
Quick ratio
8.3
Net debt/EBITDA
0.78
Margins
Efficiency
Dividend
EBITDA margin
-2,601.7%
Gross margin
100%
Net margin
-2,617.1%
Operating margin
-2,868.8%
Return on assets
-46.7%
Return on equity
-50.4%
Return on invested capital
-85%
Return on capital employed
-48.4%
Return on sales
-2,617.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRAX stock price
How has the Praxis Precision Medicines stock price performed over time
Intraday
2.15%
1 week
9.91%
1 month
8.47%
1 year
-4.5%
YTD
-45.09%
QTD
11.59%
Financial performance
How have Praxis Precision Medicines's revenue and profit performed over time
Revenue
$8.12M
Gross profit
$8.12M
Operating income
-$233.01M
Net income
-$212.56M
Gross margin
100%
Net margin
-2,617.1%
The operating income has dropped by 79% year-on-year and by 16% since the previous quarter
The net income has plunged by 70% YoY and by 16% from the previous quarter
The net margin has surged by 54% year-on-year but it has declined by 22% since the previous quarter
PRAX's operating margin has surged by 52% year-on-year but it is down by 23% since the previous quarter
Price vs fundamentals
How does PRAX's price correlate with its fundamentals
Growth
What is Praxis Precision Medicines's growth rate over time
Valuation
What is Praxis Precision Medicines stock price valuation
P/E
N/A
P/B
1.94
P/S
109.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
85.73
PRAX's EPS is up by 28% year-on-year but it is down by 6% since the previous quarter
PRAX's equity has soared by 91% YoY
PRAX's P/B is 22% below its 5-year quarterly average of 2.5 and 16% below its last 4 quarters average of 2.3
The price to sales (P/S) is 68% less than the last 4 quarters average of 344.0
The revenue has declined by 5% since the previous quarter
Efficiency
How efficient is Praxis Precision Medicines business performance
The company's return on invested capital has surged by 91% YoY and by 6% QoQ
PRAX's return on sales has surged by 54% year-on-year but it is down by 22% since the previous quarter
Praxis Precision Medicines's ROE has soared by 51% YoY
Praxis Precision Medicines's ROA has increased by 46% YoY
Dividends
What is PRAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRAX.
Financial health
How did Praxis Precision Medicines financials performed over time
The total assets has soared by 91% YoY
PRAX's total liabilities has surged by 91% year-on-year and by 4.9% since the previous quarter
The debt is 100% smaller than the equity
The debt to equity has dropped by 100% year-on-year
PRAX's equity has soared by 91% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.